Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.47 |
| ▸ | HTR3B | O95264 | 3/20 | 0.47 |
| ▸ | HTR3A | P46098 | 3/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3216346 | 0.81 | TAAR1 (0.57) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL2256351 | 0.79 | PNMT (0.58) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL2216304 | 0.77 | PNMT (0.56) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL2436 | 0.76 | — | — | |
| SCHEMBL5733314 | 0.76 | PNMT (0.60) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL29353832 | 0.76 | — | — | |
| Bromide SCHEMBL1301106 | 0.76 | PNMT (0.54) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL12050856 | 0.75 | TAAR1 (0.74) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL3300276 | 0.75 | PNMT (0.65) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL1001013 | 0.74 | PNMT (0.58) | PNMTTAAR1IDO1CYP3A4AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137162-B1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-08-01 | — | — | EP | disclosed |
| US-8536168-B2 | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-2137162-A1 | ORGANIC COMPOUNDS AND THEIR USES | Novartis Ag (CH) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008110611-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | PNMT 1050/4885TAAR1 4760/4885IDO1 532/4885 |
| US-20100069368-A1 | Organic Compounds and Their Uses | SHH, GLI1, VHL | PNMT 1194/4885TAAR1 3136/4885IDO1 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.